These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 15466914)
1. The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge. Ferrant JL; Benjamin CD; Cutler AH; Kalled SL; Hsu YM; Garber EA; Hess DM; Shapiro RI; Kenyon NS; Harlan DM; Kirk AD; Burkly LC; Taylor FR Int Immunol; 2004 Nov; 16(11):1583-94. PubMed ID: 15466914 [TBL] [Abstract][Full Text] [Related]
2. The effect of simultaneous CD154 and LFA-1 blockade on the survival of allogeneic islet grafts in nonobese diabetic mice. Berney T; Pileggi A; Molano RD; Poggioli R; Zahr E; Ricordi C; Inverardi L Transplantation; 2003 Dec; 76(12):1669-74. PubMed ID: 14688513 [TBL] [Abstract][Full Text] [Related]
3. The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Toubi E; Shoenfeld Y Autoimmunity; 2004; 37(6-7):457-64. PubMed ID: 15621572 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys. Gobburu JV; Tenhoor C; Rogge MC; Frazier DE; Thomas D; Benjamin C; Hess DM; Jusko WJ J Pharmacol Exp Ther; 1998 Aug; 286(2):925-30. PubMed ID: 9694951 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic CD154 antibody for lupus: promise for the future? Kelsoe G J Clin Invest; 2003 Nov; 112(10):1480-2. PubMed ID: 14617748 [TBL] [Abstract][Full Text] [Related]
6. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. Grammer AC; Slota R; Fischer R; Gur H; Girschick H; Yarboro C; Illei GG; Lipsky PE J Clin Invest; 2003 Nov; 112(10):1506-20. PubMed ID: 14617752 [TBL] [Abstract][Full Text] [Related]
7. Anti-CD25 mAb, anti-IL2 mAb, and IL2 block tolerance induction through anti-CD154 mAb and rapamycin in xenogeneic islet transplantation. Pan H; Lu HM; Hu WM; Tian BL; Liu XB; Zhang ZD; Mai G Transplant Proc; 2007 Dec; 39(10):3452-4. PubMed ID: 18089405 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation. Schuler W; Bigaud M; Brinkmann V; Di Padova F; Geisse S; Gram H; Hungerford V; Kleuser B; Kristofic C; Menninger K; Tees R; Wieczorek G; Wilt C; Wioland C; Zurini M Transplantation; 2004 Mar; 77(5):717-26. PubMed ID: 15021835 [TBL] [Abstract][Full Text] [Related]
10. Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis. Quezada SA; Eckert M; Adeyi OA; Schned AR; Noelle RJ; Burns CM Arthritis Rheum; 2003 Sep; 48(9):2541-54. PubMed ID: 13130474 [TBL] [Abstract][Full Text] [Related]
11. CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study. Shock A; Burkly L; Wakefield I; Peters C; Garber E; Ferrant J; Taylor FR; Su L; Hsu YM; Hutto D; Amirkhosravi A; Meyer T; Francis J; Malcolm S; Robinson M; Brown D; Shaw S; Foulkes R; Lawson A; Harari O; Bourne T; Maloney A; Weir N Arthritis Res Ther; 2015 Sep; 17(1):234. PubMed ID: 26335795 [TBL] [Abstract][Full Text] [Related]
12. FcR interactions do not play a major role in inhibition of experimental autoimmune encephalomyelitis by anti-CD154 monoclonal antibodies. Nagelkerken L; Haspels I; van Rijs W; Blauw B; Ferrant JL; Hess DM; Garber EA; Taylor FR; Burkly LC J Immunol; 2004 Jul; 173(2):993-9. PubMed ID: 15240687 [TBL] [Abstract][Full Text] [Related]
13. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation. Li JM; Gorechlad J; Larsen CP; Waller EK Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205 [TBL] [Abstract][Full Text] [Related]
14. Costimulatory molecule CD154 in systemic lupus erythematosus and rheumatoid arthritis. Therapeutic perspectives. Dejica DI; Manea EM Roum Arch Microbiol Immunol; 2006; 65(1-2):66-74. PubMed ID: 17877113 [TBL] [Abstract][Full Text] [Related]
15. Immunotherapy targeting the CD40/CD154 costimulatory pathway for treatment of autoimmune disease. Howard LM; Miller SD Autoimmunity; 2004 Aug; 37(5):411-8. PubMed ID: 15621565 [TBL] [Abstract][Full Text] [Related]
17. The CD40-CD154 co-stimulation pathway mediates innate immune injury in adriamycin nephrosis. Lee VW; Qin X; Wang Y; Zheng G; Wang Y; Wang Y; Ince J; Tan TK; Kairaitis LK; Alexander SI; Harris DC Nephrol Dial Transplant; 2010 Mar; 25(3):717-30. PubMed ID: 19889873 [TBL] [Abstract][Full Text] [Related]
19. Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolism. Nakamura M; Tanaka Y; Satoh T; Kawai M; Hirakata M; Kaburaki J; Kawakami Y; Ikeda Y; Kuwana M Rheumatology (Oxford); 2006 Feb; 45(2):150-6. PubMed ID: 16188945 [TBL] [Abstract][Full Text] [Related]
20. Tolerance induction by the blockade of CD40/CD154 interaction in pemphigus vulgaris mouse model. Aoki-Ota M; Kinoshita M; Ota T; Tsunoda K; Iwasaki T; Tanaka S; Koyasu S; Nishikawa T; Amagai M J Invest Dermatol; 2006 Jan; 126(1):105-13. PubMed ID: 16417225 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]